Naloxone 3-methylether API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Naloxone 3-methylether API 131830-09-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Naloxone 3-methylether. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Naloxone 3-methylether
- Synonyms:
- Naloxone Methyl Ether
- Cas Number:
- 131830-09-6
- DrugBank number:
- Unique Ingredient Identifier:
Naloxone 3-methylether is a type of Opioid antagonists
Opioid antagonists are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) that play a vital role in the management and treatment of opioid-related disorders. These powerful substances bind to opioid receptors in the brain, blocking the effects of opioids and reversing their potentially life-threatening effects.
Opioid antagonists work by competitively binding to opioid receptors, preventing opioids from attaching to these receptors and inhibiting their activity. This mechanism of action effectively counteracts the effects of opioids, including pain relief, sedation, and respiratory depression. By blocking the receptors, opioid antagonists can rapidly reverse the effects of opioid overdose, providing a vital emergency intervention.
One of the widely used opioid antagonists is naloxone, a highly effective and fast-acting medication. Naloxone is commonly administered in emergency settings, such as hospitals and ambulances, as well as by first responders and bystanders. Its rapid onset of action and short duration make it an essential tool for reversing opioid overdoses, potentially saving lives.
Opioid antagonists not only serve as a critical intervention for overdose cases but also have applications in the management of opioid addiction. By blocking the rewarding effects of opioids, these pharmaceutical APIs can help reduce cravings and prevent relapse in individuals undergoing opioid dependence treatment.
In conclusion, opioid antagonists are indispensable pharmaceutical APIs in combating the devastating effects of opioids. Their ability to bind to opioid receptors and counteract the effects of opioids makes them essential in both emergency situations and addiction treatment. Naloxone, among other opioid antagonists, stands as a crucial tool in saving lives and addressing the opioid crisis.
